Effect of High-Definition Transcranial Direct Current Stimulation in patients of Schizophrenia having predominantly formal thought disorder

Adjunctive High-Definition Transcranial Direct Current Stimulation on Left Inferior Frontal Gyrus in Patients of Schizophrenia Having predominantly formal thought disorder: A Randomised Sham Controlled study - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/09/057277

Enrollment

Registered

2023-09-06

Start date

Unknown

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F209- Schizophrenia, unspecified

Interventions

Intervention1: High Definition Transscranial Direct Current Stimulation: HD-tDCS was administered using standard equipment (Starstim 32, Neuroelectrics BE, Spa.) using stringent safety measures. 2?mA

inner radius 6 mm) were arranged on the scalp with the aid of an EEG cap and plastic casing to secure the electrode positions. The central electrode, designated to be the cathode, will be placed at F7

Eligibility

Inclusion criteria

Inclusion criteria: 1.Diagnosis of Schizophrenia using Diagnostic Criteria for Research (DCR) of International Classification of Disease-10th edition (ICD-10, WHO 1993). 2.Scale for the Assessment of Thought, Language, and Communication (TLC) score of more than equal to 2 3.Age between 18-60 years of either sex. 4.Right-handed 5.Patient should be on a stable dose of at least 600mg equivalent dose of antipsychotics for 2 weeks 6.Patients giving written informed consent.

Exclusion criteria

Exclusion criteria: 1.Presence of co-morbid medical, neurological, or other psychiatric disorder(s). 2.Subjects who have received ECT in the past 6 months. 3.Patient with the presence of a pacemaker or other electronic implant, metal or magnetic objects in the brain 4.Patient with substance dependence (except nicotine and caffeine)

Design outcomes

Primary

Measure	Time frame
improvement in formal thought disorder in patients of schizophrenia after application of hd-tDCS as assessed by reduction in scores of Thought & language disorder scale(TALD) at baseline, at 2 weeks & at 4 weeksTimepoint: improvement in formal thought disorder in patients of schizophrenia after application of hd-tDCS as assessed by reduction in scores of Thought & language disorder scale(TALD) at baseline, at 2 weeks & at 4 weeks	—

Measure

Time frame

improvement in formal thought disorder in patients of schizophrenia after application of hd-tDCS as assessed by reduction in scores of Thought & language disorder scale(TALD) at baseline, at 2 weeks & at 4 weeksTimepoint: improvement in formal thought disorder in patients of schizophrenia after application of hd-tDCS as assessed by reduction in scores of Thought & language disorder scale(TALD) at baseline, at 2 weeks & at 4 weeks

—

Secondary

Measure	Time frame
assess & compare the severity of positive & negative symptoms on the positive & negative syndrome scale for schizophrenia PANSS & clinical & clinical Global Impression schizophrenia CGI scale at baseline, at 2 weeks & at 4 weeksTimepoint: assess & compare the severity of positive & negative symptoms on the positive & negative syndrome scale for schizophrenia PANSS & clinical & clinical Global Impression schizophrenia CGI scale at baseline, at 2 weeks & at 4 weeks	—

Measure

Time frame

assess & compare the severity of positive & negative symptoms on the positive & negative syndrome scale for schizophrenia PANSS & clinical & clinical Global Impression schizophrenia CGI scale at baseline, at 2 weeks & at 4 weeksTimepoint: assess & compare the severity of positive & negative symptoms on the positive & negative syndrome scale for schizophrenia PANSS & clinical & clinical Global Impression schizophrenia CGI scale at baseline, at 2 weeks & at 4 weeks

—

Countries

India

Contacts

Public ContactDr Sanjay Kumar Munda

Central Institute of Psychiatry

drsanjaymunda@gmail.com8797641082

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026